PowerUp Acquisition Corp. - PWUP STOCK NEWS

Aspire Biopharma and PowerUp Acquisition Corp. (Nasdaq: PWUP) have completed their previously announced business combination, which was approved by PowerUp stockholders on January 31, 2025, and closed on February 17, 2025. Starting February 20, 2025, Aspire Biopharma will trade on the Nasdaq Global Market under the ticker symbols 'ASBP' (common stock) and 'ASBPW' (warrants).

The merger is expected to enhance Aspire's access to capital, enabling the company to expand its product development, accelerate strategic partnerships, and advance its fast-absorbing aspirin product for cardiac incidents, which management believes could receive FDA fast-track approval.

Aspire Biopharma and PowerUp Acquisition Corp (Nasdaq: PWUP) have announced a business combination agreement to create a Nasdaq-listed biopharmaceutical company. The transaction values Aspire at approximately $316 million pre-money equity value. Aspire focuses on developing products using novel delivery mechanisms to enhance the efficacy of FDA-approved drugs, nutraceuticals, and supplements.

The combined company, expected to be named Aspire Biopharma Holdings, Inc., plans to list on Nasdaq under the ticker symbol 'ASPH'. The merger is anticipated to complete by Q4 2024 or early Q1 2025. Aspire's lead product, Instaprin™, is a fast-acting, pH-neutral aspirin formulation targeting cardiology emergencies and pain management. The company plans to file a 505(b)(2) New Drug Application with the FDA for Instaprin™.

Aspire Biopharma, a developer of disruptive drug delivery technology, and PowerUp Acquisition Corp. (Nasdaq: PWUP) have signed a non-binding letter of intent for a potential business combination. The combined public company would be listed on a national securities exchange. Aspire, founded in 2021, focuses on novel delivery mechanisms for FDA-approved drugs, nutraceuticals, and supplements.

Aspire's lead product, Instaprin™, is a fast-acting, pH-neutral aspirin formulation addressing cardiology emergencies and pain management. The company plans to file a 505(b)(2) New Drug Application with the FDA. Aspire's pipeline includes various pharmaceutical and nutraceutical applications, such as a Viagra/Cialis combination and treatments for traumatic brain injury.

The proposed business combination aims to increase Aspire's market visibility and access to capital for product development. Both companies are working towards finalizing a definitive agreement, subject to various conditions and regulatory approvals.

PowerUp Acquisition Corp. (Nasdaq: PWUP) announced that on June 3, 2024, it received a notice from Nasdaq regarding non-compliance with the timely filing of its Quarterly Report on Form 10-Q for the period ending March 31, 2024. The company was required to submit a compliance plan by August 2, 2024. However, on June 5, 2024, PowerUp filed the delayed report with the SEC and believes it has regained compliance with Nasdaq's listing requirements.

PowerUp Acquisition Corp. (Nasdaq: PWUP) has rescheduled its extraordinary general meeting of shareholders to 2:00 p.m. Eastern Time on May 22, 2024. Originally slated for May 17, 2024, and later moved to May 21, 2024, this further postponement aims to allow shareholders to vote on extending the deadline for completing a business combination from May 23, 2024, to February 17, 2025. All other details of the meeting remain unchanged. Shareholders have until 5:00 p.m. Eastern Time on May 20, 2024, to submit their shares for redemption. For assistance, shareholders can reach out to Issuer Direct

PowerUp Acquisition Corp. (Nasdaq: PWUP) has postponed its extraordinary general meeting of shareholders from May 17, 2024, to May 21, 2024, at 9:00 a.m. Eastern Time. The meeting will ask shareholders to vote on extending the deadline to complete an initial business combination from May 23, 2024, to February 17, 2025. The location, record date, and purpose of the meeting remain unchanged. Shareholders now have until 5:00 p.m. Eastern Time on May 17, 2024, to submit their shares for redemption and may withdraw previously submitted requests by contacting the transfer agent.

PowerUp Acquisition Corp. and Visiox Pharmaceuticals, Inc. have announced the filing of a registration statement with the SEC for a proposed business combination. The closing of the transaction is subject to approval by PowerUp's shareholders, satisfaction of conditions in the definitive agreement, and other customary closing conditions. Upon closing, Visiox will become a wholly-owned subsidiary of Visiox Holdings, with their stock and warrants expected to be listed on Nasdaq under the symbols 'VSXP' and 'VSXPW'.

Visiox Pharmaceuticals, Inc. (Nasdaq: VSXP) and PowerUp Acquisition Corp. (Nasdaq: PWUP) have announced a definitive agreement for a business combination that will result in Visiox becoming a publicly traded company on the Nasdaq Capital Market. The business combination is expected to close in the first quarter of 2024, and upon closing, the combined company will be named Visiox Holdings, Inc. with its common stock and warrants expected to be listed on Nasdaq under the ticker symbols VSXP and VSXPW, respectively. Visiox's pipeline includes treatments for ocular hypertension, open angle glaucoma, and post-surgical inflammation and pain, addressing highly prevalent disease states in need of new treatment options. The company's CEO, Ryan Bleeks, expressed anticipation that the funds from this transaction will help accelerate the commercialization of key drug candidates.